Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

1.03USD
25 May 2017
Change (% chg)

$-0.01 (-0.96%)
Prev Close
$1.04
Open
$1.05
Day's High
$1.06
Day's Low
$1.01
Volume
75,450
Avg. Vol
97,679
52-wk High
$3.38
52-wk Low
$0.90

CYTX.OQ

Chart for CYTX.OQ

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for CYTX.OQ.

Overall

Beta: 2.48
Market Cap(Mil.): €30.11
Shares Outstanding(Mil.): 32.48
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 31.25 17.42
EPS (TTM): -7.85 -- --
ROI: -78.90 12.78 -5.45
ROE: -286.17 15.27 -4.73

BRIEF-Cytori Therapeutics completes follow up monitoring visits in FDA approved late-stage STAR trial

* Cytori Therapeutics Inc - now completed all 48 week follow up monitoring visits in its U.S. FDA approved phase III star trial Source text for Eikon: Further company coverage:

May 23 2017

BRIEF-Cytori Therapeutics files for mixed shelf of up to $100 mln

* Files for mixed shelf of up to $100.0 million - SEC filing Source text (http://bit.ly/2pGYfZe) Further company coverage:

May 12 2017

BRIEF-Cytori Q1 adjusted loss per share $0.26 excluding items

* Cytori reports first quarter 2017 business and financial results

May 11 2017

BRIEF-Cytori Therapeutics announces follow up data of ADRCs treatment in post prostatectomy erectile dysfunction

* Cytori Therapeutics Inc - one year follow up data of adrcs (cytori cell therapy) treatment in post prostatectomy erectile dysfunction

May 10 2017

BRIEF-Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract

* Cytori receives U.S. FDA approval for burn clinical trial related to BARDA contract Source text for Eikon: Further company coverage:

Apr 10 2017

BRIEF-Cytori appoints CEO of Cerium Pharmaceuticals to board

* Cytori Therapeutics -Lapointe is a co-founder and currently serves as ceo of Cerium Pharmaceuticals Source text for Eikon: Further company coverage:

Apr 03 2017

BRIEF-Cytori reports Q4 2016 total revenues $3 million

* Cytori reports fourth quarter and full year 2016 business and financial results

Mar 23 2017

BRIEF-Azaya Therapeutics Reports 5 pct passive stake in Cytori Therapeutics

* Azaya Therapeutics Inc reports 5 percent passive stake in Cytori Therapeutics as on Feb. 15, 2017 Source text:(http://bit.ly/2mg6n5N) Further company coverage:

Feb 24 2017

BRIEF-Cytori Therapeutics receives small business designation

* Cytori Therapeutics - FDA division of industry consumer education (DICE) has granted small business status to cytori therapeutics for fiscal year 2017 Source text for Eikon: Further company coverage:

Feb 06 2017

BRIEF-Cytori to acquire proprietary nanoparticle development platform

* Cytori to acquire proprietary nanoparticle development platform to enhance regenerative medicine leadership position

Jan 19 2017

More From Around the Web

Earnings vs. Estimates